F. Koinis, V. Georgoulias
Chairs: V. Georgoulias, F. Koinis
Personalized Medicine: a new and evolving reality in clinical oncology Ch. Antonopoulos
Chairs: G. Lypas, Th. Rampias
09.30-09.50 Τhe emerged importance of pathologist beyond the diagnostic workup
D. Papachristou
09.50-10.10 The need for NGS analysis using polygenic panels for tumor molecular profiling G. Nasioulas
10.10-10.30 RNA sequence: Could be emerged as a new tool for personalized treatment in cancer? Str. Kosmidis
10.30-10.50 HRD score: A new biomarker for PARP inhibitors P. Constantoulakis
10.50-11.00 Discussion
Coffee Break
Chairs: V. Georgoulias, F. Papageorgiou
The importance of Liquid Biopsy as a tool for the understanding of the natural history and the metastatic process E. Lianidou
Chairs: A. Markou, N. Xenidis
12.00-12.20 The phenotypic heterogeneity of Circulating Tumor Cells in breast cancer G. Kallergi
12.20-12.40 The molecular heterogeneity of Circulating Tumor Cells in breast cancer A. Strati
12.40-13.00 ESR1 mutation as a marker for hormone resistance treatment D. Stergiopoulou
13.00-13.10 Discussion
Chairs: E. Lianidou, D. Tryfonopoulos
13.10-13.30 Clinical applications of Circulating Tumor Cells in breast cancer N. Xenidis 13.30-13.50 Clinical applications of ctDNA in breast cancer O. Fiste
13.50-14.00 Discussion
Light Lunch
Chairs: A. Strati, F. Koinis
15.00-15.20 The clinical relevance of CTC in prostate cancer Z. Zafeiriou
15.20-15.40 The emerging importance of CTC in NSCLC A. Markou
15.40-16.00 the exosomes as a potential tool of tumor biomarkers A. Xagara
16.00-16.10 Discussion
Chairs: G. Nasioulas, D. Stefanou
16.10-16.30 Newer biomarkers in NSCLC (EGFR exon 20 mut, KRAS mut, MET exon 14 mut) G. Oikonomopoulos
16.30-16.50 Newer biomarkers in NSCLC (NTRK, RET, HER2 mut) E.-G. Fergadis
16.50-17.00 Discussion
Coffee break
Chairs: A. Kotsakis, Th. Tegos
17.30-17.50 Clinical applications of liquid biopsy in NSCLC F. Papageorgiou
17.50-18.10 Monitoring of ctDNA for treatment efficacy in colorectal cancer patients I. Samaras
18.10-18.30 Monitoring the Minimal Residual Disease using Liquid Biopsy assays A. Voutsina
18.30-18.50 The Signatera R platform for the detection of MRD N.Tsoulos
18.50-19.00 Discussion
Chairs: P. Constantoulakis, O. Katopodis
09.00-09.20 Emerging molecular subgroups in Colorectal cancers using NGS technology A. Assi
09.20-09.40 Biomarkers in pancreatic and biliary tract carcinomas E. Karatrasoglou
09.40-10.00 The NTRK fusions as a biomarker for personalized treatment A. Kyriazoglou
10.00-10.10 Discussion
Chairs: I. Vamvakaris, Ch. Valavanis
10.10-10.30 The prognostic and predictive value of TILs I. Pateras
10.30-10.50 Is PD-L1 a real biomarker for treatment with ICIs? Ch. Masaoutis
10.50-11.10 Tumor Mutation Burden (TMB): When and How G. Tsaousis
11.10-11.30 Intergrading MSI/MMR testing in the daily clinical practice A. karampeazis
11.30-11.50 Immunoscore: A new tool for treatment de-escalation in early stage colorectal cancer D. Hatzibougias
11.50-12.10 Discussion
Chairs: A. Kotsakis, F. Koinis
The emergence of Tissue-Agnostic treatment in clinical oncology N. Pistamaltzian
Closing Remarks